Information Letter of the European LeukemiaNet

Information Letter No.:

Content:

• WP4 – CML: Update of ELN treatment recommendations for chronic myeloid leukemia
• EUTOS for CML: A successful collaboration
• WP5 – AML: Is there a role for immunotherapy in maintaining complete remission in acute myeloid leukemia?
• WP5 – AML: Developments in APL
• WP5 – AML: Prospective Assessment of Outcome Determinants in AML: An EL N Pilot Project
• WP14 – SCT: Main factors predicting outcome after hematopoietic stem cell transplantation
• WP11 – Cytogenetics : Polymorphisms of DNA repair and detoxification genes in chronic lymphocytic leukemia
• WP2 – ELIC: EL IC for impact assessment of EU -directive on good clinical practice
• Network News: ELN Foundation, ALL: Acute lymphoblastic leukemia, Dates/Meetings, Ongoing studies of the European LeukemiaNet in the ELTR, Recommendations and Guidelines

• Project 4 CML: European Registry of chronic myelogenous leukemia patients in failure after imatinib therapy
• Project 5 AML: ChIP- chip microarrays to study the epigenome in leukemia
• Project 6 ALL: Important steps towards diagnostic standardization
• Project 7 CLL: New aspects of the updated guidelines for the diagnosis and treatment of chronic lymphocytic leukemia
• Project 13 Gene Profiling: Gene Analysis Platform (GAP) for ELN
• Network News: 1st ELN Workshop on international investigator-initiates-trials, ELTR News, A novel collaboration between academia and industry to improve treatment in CML, Dates & Meetings, Ongoing studies

• Project 4 CML: The CML Group within the European Leukemia Network agreed on a long term Collaboration with Novartis
• Project 5 AML: The AML Intergroup: A Model of Cross-Trial Networking
• Project 6 ALL: Progress in Initiation of Paneuropean Trials
• Project 7 CLL: Finding Solutions for IGHV gene mutational Analysis in CLL
• Project 11 Cytogenetics: Correlation of whole Genome tiling Resolution Array CGH with Affymetrix Array Expression Analysis in AML/MDS Patients with 11q/MLL Amplification
• Project 2 ELIC: The German Leukemia and Lymphoma Patients’ Association and the European Cancer Patient Coalition
• Project 8 MDS: Development of a frailty Index for elderly Patients with MDS and AML by applying a multimodal geriatric Assessment including Quality of life Evaluation
• Project 6 ALL:Patient Information for ALL in Eight European Languages
• Project 15 Supportive Care: New Guidelines for Preventing and Treating infectious Diseases in leukemic Patients

• Project 4 CML: Recommendations for treatment of CML
• Projects 10 CLL & 13 Geneprofiling: Joint meeting at MLL, Munich
• Project 12 MRD: Development of real-time PCR
• Project 2 ELIC: European Leukemia Trial Registry
• Project 8 MDS: MDS Registry
• Project 9 CMPD: Consensus definition of resistance to Hydroxyurea in ET
• Project 11 Cytogenetics: t(16;21) (AML1-MTD16) with karyotype evolution identified in a de novo AML M1 patient
• Project 14 SCT:The unmet need for infrastructure in hematopoetic stem cell transplantation (HSCT)

• Project 6 ALL: Acute lymphoblastic leukemia
• Project 7 CLL: European Research Initiative on Cll (ERIC)
• Project 8 MDS: Actual state of WP 8 (MDS)
• Project 11 Cytogenetics: Analysis of AMl/MDS Patient with 11q/Mll Gene Amplification
• Project 14 Stem Cell Therapy: Stem Cell Transplantation Activity in europe 2004
• Project 2 ELIC: Clinical Trials Registry
• Project 2 ELIC: Re-launch of the ELN-Website

• Project 1 NMC: News from the Network Management Center Dates, Meetings
• Project 2 ELIC: Services provided by the European Leukemia Information Center
• Project 4 CML: Actual state of WP 4 (CML)
• Project 5 AML: Experiences from a Network of AML Trials using General Up-Front Randomization and a Common Standard Treatment Arm
• Project 11 Cytogenetics: Consensus protocols for cytogenetic diagnostics in leukemia
• Project 9 CMPD: Progress report Chronic Myeloproliferative Disorders
• Project 10 Diagnostic platform: European Immunophenotyping Panels
• Project 16 New Drugs:ELTRA: European Leukemia Treatment Research Association